Cube Labs S.P.A.
MMIL:CUBE2.26
EUR
0.00
(0.00%)
Cube Labs S.P.A.
MIL:CUBE
(Euronext Milan)
Recent
price
2.26
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Cube Labs S.p.A. is an Italian life sciences venture builder and technology transfer company that specializes in creating, developing, and commercializing early-stage spin-offs and proprietary healthcare technologies. Founded in 2013 and headquartered in Rome, Italy, the company bridges the gap between academic scientific research and the global market by identifying high-potential intellectual property developed by universities and research institutes, transforming discoveries into commercially viable healthcare enterprises. Cube Labs operates across the biotechnology, medical device, in vitro diagnostics, and digital health sectors, targeting pharmaceutical corporations, healthcare systems, research organizations, and institutional life sciences investors across Italy, broader Europe, the Middle East, and other international markets. The company delivers comprehensive technology transfer and venture building services while developing a diversified pipeline of clinical and medical solutions through its portfolio subsidiaries. Core offerings and product categories comprise: Biotechnology and Therapeutics, including the development of small molecules, biologics, and nutraceutical formulations targeting oncology, infectious diseases, autoimmune disorders, and regenerative medicine; Medical Devices and Diagnostics, comprising non-invasive screening systems, point-of-care diagnostic platforms, biosensors, and specialized surgical and orthopaedic biomaterials; Digital Health and Telemedicine, encompassing artificial intelligence-driven diagnostic support software, clinical data analytics platforms, remote patient monitoring tools, and digital therapeutic applications; and Technology Transfer and Venture Incubation Services, which include proprietary intellectual property scouting and evaluation; patent strategy, filing, and portfolio management; preclinical and translational research management; regulatory strategy and CE/FDA compliance roadmapping; corporate structuring and spin-off administration; and grant acquisition, seed capital structuring, and industrial licensing. In recent developments, Cube Labs has significantly expanded its commercial and corporate footprint following its initial public offering on the Euronext Growth Milan Professional Segment (Ticker: CUBE). Over the past two years, the company has executed several strategic capital raises and warrant exercises to accelerate the clinical and preclinical validation of its pipeline ventures. Operationally, Cube Labs has advanced international expansion initiatives, establishing strategic partnerships and collaborative joint ventures in the Middle East, including the United Arab Emirates and Saudi Arabia, to foster bilateral healthcare innovation, technology deployment, and clinical co-development. Additionally, the company has expanded its network of academic alliances with leading Italian and European universities, secured international patents across multiple portfolio companies in oncology and diagnostic sensing, and initiated corporate governance and sustainability enhancements to transition select high-maturity portfolio assets toward independent external financing rounds and commercial licensing agreements.